Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves' disease in different periods.

Autor: Zhao A; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Zhang J; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Xue J; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Lu X; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Wang Q; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Ji T; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Yang L; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Yu Y; School of Public Health, Health Science Center of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China., Yang A; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. dryangaimin@163.com.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Dec 28; Vol. 14 (1), pp. 31148. Date of Electronic Publication: 2024 Dec 28.
DOI: 10.1038/s41598-024-82521-5
Abstrakt: In China, due to the risks of hypothyroidism after radioiodine treatment, radioiodine is not commonly used as a first-line treatment. In this study, factors influencing the development of hypothyroidism after 131 I therapy for Graves' hyperthyroidism were evaluated. This was a retrospective study with a 12-month follow-up. Retrospectively, we investigated 1,264 patients with diagnosed Graves' disease who received 131 I therapy using the Marinelli-Quimby formula. The first three months after 131 I therapy, hypothyroidism risk was higher among patients with lighter thyroid weight, higher levels of thyroglobulin antibody (TGAb), and shorter durations of Antithyroid drug (ATD) treatment before 131 I therapy (P < 0.05). After 6 months, patients with lighter thyroid weight, shorter ATD treatment duration before 131 I therapy, and higher iodine intake showed an increased risk of hypothyroidism. (P < 0.05). After one year, lower 24-h iodine uptake was the only risk factor for hypothyroidism (P < 0.05). Our results show that   131 I is an effective therapy for GD. Even if over time, the occurrence of hypothyroidism may ultimately depend on the patients' radiosensitivity to 131 I before treatment. But in the first 3 to 6 months or even one year, we can still take measures to effectively improve the quality of life of patients.
Competing Interests: Declarations. Consent statement: Due to the retrospective nature of the study, Committee of Medical Research, Xi’an Jiaotong University waived the need of obtaining informed consent and ethic approval. All methods were performed in accordance with the relevant guidelines and regulations. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: